Log in
Enquire now
‌

US Patent 11986500 Bacteriotherapy for clostridium difficile colitis

Patent 11986500 was granted and assigned to Rebiotix on May, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Rebiotix
Rebiotix
0
Date Filed
December 18, 2023
0
Date of Patent
May 21, 2024
0
Patent Applicant
Rebiotix
Rebiotix
0
Patent Application Number
18544083
0
Patent Citations
‌
US Patent 7607776 Digital eye bank for virtual clinic trials
0
‌
US Patent 7993682 Electrolyte purgative
0
‌
US Patent 8058418 Polynucleotides encoding heavy and light chains of antibodies to OPGL
0
‌
US Patent 8110177 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
0
‌
US Patent 8460648 Probiotic recolonisation therapy
0
‌
US Patent 8722088 Pharmaceutical compositions and methods for the treatment of prostate cancer
0
‌
US Patent 8772242 Therapy for enteric infections
0
‌
US Patent 8906668 Synergistic bacterial compositions and methods of production and use thereof
0
‌
US Patent 9011834 Compositions and methods
0
‌
US Patent 9433651 Microbiota restoration therapy (MRT), compositions and methods of manufacture
0
•••
Patent Citations Received
‌
US Patent 12102655 Bacteriotherapy for clostridium difficile colitis
0
Patent Inventor Names
Edwin J. Hlavka
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11986500
0
Patent Primary Examiner
‌
David W Berke-Schlessel
0

Find more entities like US Patent 11986500 Bacteriotherapy for clostridium difficile colitis

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.